American Society of Clinical Oncology (ASCO) 2025 Symposia

 
Virtual Simulcast
 
In-Person
 
Free CME/CE Credits

CCO Oncology Chicago 2025

Join us live in Chicago or virtually to discover the latest breakthroughs in oncology and hematology! Expert faculty will facilitate exciting satellite symposia, where you will interact with other professionals and receive practical guidance on a wide range of malignancies.

The best part? You do not need to be an ASCO registrant to join our events! Claim free CME/CE credits and receive complimentary slides to support your presentation needs.

 

Dates May 30th - May 31st

 

Time Varies per Event
Timezone Converter ›

 

Location Hilton Chicago
720 S. Michigan Ave.
Chicago, IL 60605

 

Bus RouteShuttle Bus Route 10:
From McCormick Place:
North - Gate 26

Event Schedule

Attend in-person or via virtual simulcast.

May

30

2025

6:30 PM - 8:30 PM Central Time (CT)

In-person

7:00 PM - 8:30 PM Central Time (CT)

Virtual

May

31

2025

Featured Faculty

Faculty

Neeraj Agarwal, MD, FASCO

  • Professor of Medicine
  • Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
  • Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research
  • Director, Center of Investigational Therapeutics
  • Director, Genitourinary Oncology Program
  • Huntsman Cancer Institute
  • University of Utah (NCI-CCC)
  • Salt Lake City, Utah
Faculty

Jesus Berdeja, MD

  • Director of Myeloma Research
  • Greco-Hainsworth Centers for Research
  • Tennessee Oncology
  • Nashville, Tennessee
Faculty

Danielle M. Brander, MD

  • Associate Professor of Medicine
  • Division of Hematologic Malignancies & Cellular Therapy
  • Department of Medicine, Duke University
  • Duke Cancer Institute
  • Durham, North Carolina
Faculty

Natalie S. Callander, MD

  • Director, Myeloma Clinical and Cellular Therapy Program
  • University of Wisconsin Carbone Cancer Center
  • Madison, Wisconsin
Faculty

Karim Fizazi, MD, PhD

  • Full Professor, University of Paris Saclay
  • President of GETUG
  • Head of the Genito-Urinary Group
  • Department of Cancer Medicine
  • Gustave Roussy
  • Villejuif, France
Faculty

Joseph W. Franses, MD, PhD

  • Assistant Professor of Medicine
  • Section of Hematology-Oncology
  • University of Chicago
  • Chicago, Illinois
Faculty

Jonathan W. Friedberg, MD

  • Director, Wilmot Cancer Institute
  • Samuel Durand Professor of Medicine and Oncology
  • University of Rochester
  • Rochester, New York
Faculty

William J. Gradishar, MD, FACP, FASCO

  • Betsy Bramsen Professor of Breast Oncology
  • Robert H. Lurie Comprehensive Cancer Center
  • Northwestern University
  • Chicago, Illinois
Faculty

Nadia Harbeck, MD, PhD

  • Director of the Breast Center
  • Department of OB&GYN and Comprehensive Cancer Center Munich
  • LMU University Hospital
  • Munich, Germany
Faculty

Alex F. Herrera, MD

  • Chief, Division of Lymphoma
  • Professor, Department of Hematology and Hematopoietic Cell Transplantation
  • Medical Director of the City of Hope Clinical Trials Office
  • Associate Medical Director of the Briskin Center for Clinical Research
  • City of Hope Medical Center
  • Duarte, California
Faculty

Carol Ann Huff, MD

  • Associate Professor of Oncology
  • Medical Director
  • Multiple Myeloma Program
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Baltimore, Maryland
Faculty

Brad Kahl, MD

  • Professor of Medicine
  • Washington University in St. Louis
  • Director of Lymphoma Program
  • Siteman Cancer Center
  • Saint Louis, Missouri
Faculty

Kara M. Kelly, MD

  • Waldemar J. Kaminski Endowed Chair of Pediatrics
  • Roswell Park Comprehensive Cancer Center
  • Division Chief and Professor of Pediatrics
  • University at Buffalo Jacobs School of Medicine and Biomedical Sciences
  • Buffalo, New York
Faculty

Rami Komrokji, MD

  • Vice Chair, Department of Malignant Hematology
  • Senior Member and Professor of Oncologic Sciences
  • H. Lee Moffitt Cancer Center
  • Tampa, Florida
Faculty

Amrita Krishnan, MD, FACP

  • Director, Judy and Bernard Briskin Center for Myeloma
  • Executive Director of Hematology
  • City of Hope Orange County
  • Professor of Hematology/HCT
  • City of Hope Cancer Center
  • Irvine, California
Faculty

Ian Krop, MD, PhD

  • Professor of Internal Medicine
  • Associate Cancer Center Director for Clinical Research
  • Chief Clinical Research Officer
  • Yale Cancer Center
  • New Haven, Connecticut
Faculty

Shaji K. Kumar, MD

  • Mark and Judy Mullins Professor of Hematological Malignancies
  • Consultant, Division of Hematology
  • Professor of Medicine
  • Chair, Myeloma, Amyloidosis and Dysproteinemia Group
  • Research Chair, Division of Hematology
  • Mayo Clinic
  • Rochester, Minnesota
Faculty

Ticiana Leal, MD

  • Associate Professor
  • Department of Hematology & Oncology
  • Director, Thoracic Medical Oncology
  • Medical Director, Clinical Trials Office
  • Winship Cancer Institute
  • Emory University
  • Vice-President/President-Elect
  • Georgia Society of Clinical Oncology
  • Atlanta, Georgia
Faculty

Sagar Lonial, MD, FACP

  • Chair and Professor
  • Department of Hematology and Medical Oncology
  • Anne and Bernard Gray Family Chair in Cancer
  • Chief Medical Officer
  • Winship Cancer Institute
  • Emory University School of Medicine
  • Atlanta, Georgia
Faculty

Erica L. Mayer, MD, MPH, FASCO

  • Director of Breast Cancer Clinical Research
  • Dana-Farber Cancer Institute
  • Associate Professor of Medicine
  • Harvard Medical School
  • Boston, Massachusetts
Faculty

Rana R. McKay, MD

  • Professor of Medicine and Urology
  • Moores Cancer Center
  • University of California San Diego
  • La Jolla, California
Faculty

Alicia K. Morgans, MD, MPH, FASCO

  • Associate Professor
  • Harvard Medical School
  • Director, Adult Survivorship Program
  • Dana-Farber Cancer Institute
  • Boston, Massachusetts
Faculty

Joanne E. Mortimer, MD

  • Vice Chair, Medical Oncology
  • Professor, Division of Medical Oncology & Experimental Therapeutics
  • Associate Director for Education and Training
  • Baum Family Professor of Women’s Cancers
  • City of Hope Comprehensive Cancer Center
  • Duarte, California
Faculty

Ruth O'Regan, MD

  • Charles A. Dewey Endowed Professor of Medicine
  • Chair, Department of Medicine, University of Rochester Medical Center
  • Physician in Chief, Strong Memorial Hospital
  • Associate Director of Education and Mentoring, Wilmot Cancer Institute
  • Rochester, New York
Faculty

Joyce O'Shaughnessy, MD

  • Celebrating Women Chair in Breast Cancer Research
  • Baylor University Medical Center
  • Chair, Breast Disease Commitee
  • Sarah Cannon Research Institute
  • Dallas, Texas
Faculty

Neehar Parikh, MD, MS

  • Associate Professor
  • Medical Director, Liver Tumor Program
  • Division of Gastroenterology & Hepatology
  • University of Michigan
  • Ann Arbor, Michigan
Faculty

Sameer A. Parikh, MBBS

  • Consultant, Division of Hematology
  • Chair, CLL Disease Team
  • Vice Chair, Lymphoid Malignancies Disease Group
  • Mayo Clinic Comprehensive Cancer Center
  • Associate Professor of Medicine and Assistant Professor of Oncology
  • Mayo Clinic Alix School of Medicine and Science
  • Rochester, Minnesota
Faculty

Charles J. Ryan, MD

  • Member and Attending
  • Department of Medicine
  • Genitourinary Oncology Service
  • Medical Director, Prostate Cancer Clinical Trials Consortium
  • Memorial Sloan Kettering Cancer Center
  • New York, New York
Faculty

Sarah L. Sammons, MD

  • Associate Director
  • Metastatic Breast Cancer Program
  • Susan F. Smith Center for Women’s Cancers
  • Assistant Professor of Medicine
  • Harvard Medical School
  • Dana-Farber Cancer Institute
  • Boston, Massachusetts
Faculty

Neal D. Shore, MD, FACS

  • Head of Genitourinary Oncology
  • START-CURC
  • Atlantic Urology Clinics Specialists
  • Myrtle Beach, South Carolina
Faculty

Mark A. Socinski, MD

  • Executive Medical Director
  • AdventHealth Cancer Institute
  • Orlando, Florida
Faculty

Mark Yarchoan, MD

  • Associate Professor of Medical Oncology
  • Division of GI Malignancies
  • Sidney Kimmel Comprehensive Cancer Center
  • Johns Hopkins University
  • Baltimore, Maryland
Faculty

Amer Zeidan, MBBS, MHS

  • Professor of Medicine
  • Chief, Division of Hematologic Malignancies
  • Yale Comprehensive Cancer Center and Smilow Cancer Hospital
  • New Haven, Connecticut

Accreditation

Expert Perspectives on Updates and Advances in Individualizing CLL/SLL Therapy Across the Disease Course
Physicians: maximum of 1.50 AMA PRA Category 1 Credits
Registered Nurses: 1.50 Nursing contact hours
Physician Assistants: maximum of 1.50 AAPA Category 1 CME credits
Pharmacists: 1.50 contact hours (0.15 CEUs)
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Mastering the Evolving Treatment Paradigm in SCLC: Expert Case Discussions to Aid Integration of Immunotherapy and Novel Targeted Therapies
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Overcoming Endocrine Resistance in HR+/HER2- MBC: Tailoring Treatment for Patients With ESR1- and PI3K/AKT/PTEN-Altered Disease Post-ET Progression
Nurse Practitioners/Nurses: 1.50 Nursing contact hours
Pharmacists: 1.50 contact hours (0.15 CEUs)
Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

New Treatments on the Horizon: Cancer Conversations on Novel Mechanisms and Emerging Treatment Options in mCRPC
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™

Challenging Treatment Paradigms in HER2-Low and HER2-Ultralow MBC: Experts Examine The Evidence to Guide Individualized Clinical Decisions
Physicians: maximum of 1.50 AMA PRA Category 1 Credit
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Novel Therapeutic Approaches and Personalized Strategies for Managing Anemia in LR-MDS
Physicians: maximum of 1.00 AMA PRA Category 1 Credits
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

CDK4/6 Inhibition in Breast Cancer: Expert Perspectives on Integrating Guideline Updates and Recent Advances Into Practice
Physicians: maximum of 1.50 AMA PRA Category 1 Credits
Registered Nurses: 1.50 Nursing contact hours
Physician Assistants: maximum of 1.50 AAPA Category 1 CME credits
Pharmacists: 1.50 contact hours (0.15 CEUs)
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care
Physicians: maximum of 1.50 AMA PRA Category 1 Credits
Registered Nurses: 1.50 Nursing contact hours
Physician Assistants: maximum of 1.50 AAPA Category 1 CME credits
Pharmacists: 1.50 contact hours (0.15 CEUs)
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Transforming Frontline Therapy in Hodgkin Lymphoma: Advancing Personalized Strategies for Optimal Outcomes
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

CELMoDs in Myeloma—What’s Here, What’s Next, and What’s on the Horizon
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Redefining HCC Treatment in the Immunotherapy Era: Expert Insights, Multimodal Innovations, and Coordinated Care for Optimal Outcomes Across the Disease Continuum
Physicians: maximum of 1.00 AMA PRA Category 1 Credit™
Physicians ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Hilton Chicago

720 S Michigan Ave
Chicago, IL 60605

Expert Perspectives on Updates and Advances in Individualizing CLL/SLL Therapy Across the Disease Course
Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC
Supported by an independent medical education grant from AbbVie. Supported by educational grants from Bristol Myers Squibb and Lilly.

Mastering the Evolving Treatment Paradigm in SCLC: Expert Case Discussions to Aid Integration of Immunotherapy and Novel Targeted Therapies
Provided by Clinical Care Options, LLC
Supported by educational grants from Amgen, Daiichi Sankyo, Inc. and Jazz Pharmaceuticals, Inc.

Overcoming Endocrine Resistance in HR+/HER2- MBC: Tailoring Treatment for Patients With ESR1- and PI3K/AKT/PTEN-Altered Disease Post-ET Progression
Provided by Clinical Care Options, LLC
Supported by educational grants from AstraZeneca, Lilly and Stemline Therapeutics, Inc.

New Treatments on the Horizon: Cancer Conversations on Novel Mechanisms and Emerging Treatment Options in mCRPC
Provided by Clinical Care Options, LLC in partnership with ZERO Prostate Cancer
Supported by educational grants from Novartis Pharmaceuticals Corporation and Pfizer, Inc.

Challenging Treatment Paradigms in HER2-Low and HER2-Ultralow MBC: Experts Examine The Evidence to Guide Individualized Clinical Decisions
Provided by Clinical Care Options, LLC
Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Novel Therapeutic Approaches and Personalized Strategies for Managing Anemia in LR-MDS
Provided by Clinical Care Options, LLC
Supported by educational grants from Bristol Myers Squibb and Geron.

CDK4/6 Inhibition in Breast Cancer: Expert Perspectives on Integrating Guideline Updates and Recent Advances Into Practice
Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC
Supported by educational grants from Lilly and Novartis.

Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care
Provided by Clinical Care Options, LLC
Supported by educational grants from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC and Sanofi.

Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches
Provided by Clinical Care Options, LLC
Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC and Pfizer Inc.

Transforming Frontline Therapy in Hodgkin Lymphoma: Advancing Personalized Strategies for Optimal Outcomes
Provided by Clinical Care Options, LLC
Supported by an educational grant from Bristol Myers Squibb.

CELMoDs in Myeloma—What’s Here, What’s Next, and What’s on the Horizon
Provided by Clinical Care Options, LLC
Supported by an educational grant from Bristol Myers Squibb.

Redefining HCC Treatment in the Immunotherapy Era: Expert Insights, Multimodal Innovations, and Coordinated Care for Optimal Outcomes Across the Disease Continuum
Provided by Clinical Care Options, LLC
Supported by educational grants from Eisai and Merck Sharp & Dohme LLC.

ASCO Disclaimer:
Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.